Combination therapy in patients with type 2 diabetes mellitus: international recommendations and own experience
Vol. 22 No. 3 (2017), ORIGINAL PAPERS
Vol. 22 No. 3 (2017)

Combination therapy in patients with type 2 diabetes mellitus: international recommendations and own experience

ORIGINAL PAPERS
Published September 28, 2017
L.K. Sokolova
SI «V.P. Komisarenko Institute of Endocrinology and Metabolism, Natl. Acad. Sci. of Ukraine»
S.V. Bolharska
SI «V.P. Komisarenko Institute of Endocrinology and Metabolism, Natl. Acad. Sci. of Ukraine»
G.V. Ostroverkhova
Novo Nordisk A/S
Pdf (Українська)

Keywords

Diabetes type 2, obesity, glucagon-like peptide‑1 receptor agonist, liraglutide

How to Cite

Sokolova, L., Bolharska, S., & Ostroverkhova, G. (2017). Combination therapy in patients with type 2 diabetes mellitus: international recommendations and own experience. Endokrynologia, 22(3), 211-218. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/80
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Chronic hyperglycaemia in the progression of Diabetes type 2 requires the intensification of hypoglycaemic therapy with the use of a combination of several drugs. According to the international recommendations, in the choice of rational combined hypoglycaemic therapy, their effectiveness and minimization of undesirable effects, namely the risk of hypoglycaemia and weight gain, are of priority. An analogue of glucagon-like peptide‑1 — liraglutide as part of combined hypoglycaemic therapy with oral medicines or
insulin provides improved glycaemic control without increasing the risk of hypoglycaemia and weight gain. Taking into account these benefits of liraglutide, the American Association of Clinical Endocrinologists and the American College of Endocrinology recommend its use as the first drug of the second line of therapy for Diabetes type 2. Conclusion. The clinical experience confirms the efficacy and safety of liraglutide (Victozа®) as part of combined glycaemic therapy in patients with Diabetes type 2, obesity and comorbidity.

Pdf (Українська)

References

1. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006 Apr;82(966): 280-4.
2. Довідник основних показників діяльності ендокринологічної служби України за 2016 рік. Ендокринологія. 2017;22(1):33 c. (Directory of main indicators of activity of the endocrinology service of Ukraine for 2016. Endokrynolohiya. 2017;22 (1):33 c.).
3. Гульчій МВ, Замолотова КО, Соколова ЛК, Бойко ОА, Сакало ОА, Власенко НГ та інші. Системний контроль глікозильованого гемоглобіну – шлях до покращення лікування і якості життя людей з цукровим діабетом. Діабет. Ожиріння. Метаболічний синдром. 2014;4:91-8. (Gulchii MV, Zamolotova KO, Sokolova LK, Boyko OA, Sakalo OA, Vlasenko NG, et al. Systemic control of glycosylated hemoglobin is a way to improve the quality of life and treatment of people with diabetes. Diabet. Ozhyrinnya. Metabolichnyy syndrom. 2014;4:91-8).
4. Standards of medical care in diabetes – 2017. Diabetes Care. 2017 Jan;40(Suppl 1):1-135.
5. Уніфікований клінічний протокол первинної та вторинної (спеціалізованої) медичної допомоги цукровий діабет 2 типу. Наказ Міністерства охорони здоров›я України від 21.12.2012 № 1118. (Unified clinical protocol for primary and secondary (specialized) medical care of type 2 diabetes. Nakaz Ministerstva okhorony zdorov’ya Ukrayiny vid 21.12.2012 № 1118.
6. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017 Feb;23(2):207-38.
7. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, openlabel trial (LEAD-6). Lancet. 2009 Jul 4;374(9683):39-47.
8. Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009;69(14):1985-2004.
9. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009 Feb 7;373(9662):473-81.
10. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009 Mar;26(3):268-78.
11. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009 Jan;32(1):84-90.
12. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009 Oct;52(10):2046-55.
13. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). DiabetesCare. 2009 Jul;32(7):1224-30.

Downloads

Download data is not yet available.